AFP
NVCR icon

Ausdal Financial Partners’s NovoCure NVCR Stock Holding History

Ausdal Financial Partners’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$22K – 760
2015
Q4 		$22K Buy
+1,000
New +$23.9K 0.01% 709

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ausdal Financial Partners's NVCR Position: Q1 2016 in Review

Ausdal Financial Partners sold out of NovoCure (NVCR) in Q1 2016, closing a stake of 1,000 shares — an estimated $22K sold.

Ausdal Financial Partners first reported a position in NVCR in Q4 2015 and held it in 1 quarter. The position peaked at $22K in Q4 2015. 58 funds tracked by Wall St. Rank hold NVCR as of Q1 2016.

  • Ausdal Financial Partners reported no remaining NovoCure position as of Q1 2016 after selling out during the quarter.
  • Ausdal Financial Partners sold 1,000 NovoCure shares in Q1 2016, an estimated $22K.
  • Ausdal Financial Partners first reported a position in NovoCure in Q4 2015 and held it in 1 quarter.
  • Ausdal Financial Partners's NovoCure position peaked at $22K in Q4 2015.
  • 58 funds tracked by Wall St. Rank held NovoCure as of Q1 2016.

Based on Ausdal Financial Partners's 13F filing for Q1 2016, filed 5 May 2016.